Aprea Therapeutics APRE 深 沪
等待开盘 08-30 09:30:00 美东时间
1.5501
-0.035
-2.20%
华盛通- 最 高1.65
- 今 开1.62
- 成交量 1.42万股
- 最 低 1.55
- 昨 收 1.585
- 总市值 902.98万
- 52周最高 5.01
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.412
- 委 比 -98.45%
- 总股本 582.53万
- 历史最高 1062.20
- 量 比 0.35
- 振 幅 6.31%
- 历史最低 1.412
- 每 手 1
- 风险率 0.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
Aprea Therapeutics announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:30 PM ET in New York. The presentation will focus on Aprea’s innovative cancer treatments targeting specific cancer cell vulnerabilities while sparing healthy cells. Aprea’s lead programs include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for s...
08-28 12:30
Aprea Therapeutics GAAP EPS of -$0.53
Aprea Therapeutics press release (NASDAQ:APRE): Q2 GAAP EPS of -$0.53. $16.5 million in cash and cash equivalents as of June 30, 2025 More on Aprea Therapeutics Seeking Alpha’s Quant Rating on Aprea T...
08-12 20:14
Aprea Therapeutics Q2 EPS $(0.53) Beats $(0.74) Estimate, Sales $118.111K Down From $561.574K YoY
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.74) by 28.86 percent. This is a 8.62 percent increase over losses of $(0.58) per share from
08-12 20:11
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
Aprea Therapeutics reported $16.5 million in cash as of June 30, 2025, and a net loss of $3.2 million. The company's lead programs, WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119, showed early signs of clinical activity, with APR-1051 achieving stable disease in three patients and ATRN-119 showing tumor shrinkage in some patients. Aprea plans to expand trials and explore combination therapies.
08-12 12:00
Aprea Therapeutics Presents APR-1051 Preclinical And Early Clinical Results In HPV+ Head And Neck Cancer
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapyInitial Phase 1 clinical update shows early
06-25 21:05
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Aprea Therapeutics reported preclinical data and a clinical update on APR-1051, a next-generation WEE1 inhibitor, for HPV+ head and neck squamous cell carcinoma (HNSCC). Preclinical studies with MD Anderson Cancer Center showed robust single-agent activity and synergistic effects when combined with anti–PD-1 therapies. APR-1051 activated immunogenic cell death and exploited HPV E6-driven vulnerabilities, offering a biomarker-driven approach. Earl...
06-25 13:00
Aprea Therapeutics Confirms Directors and Accounting Firm
Aprea Therapeutics ( ($APRE) ) has provided an update. At the 2025 annual meeti...
06-10 04:42
Aprea Therapeutics shares are trading higher on continued strength after the company reported a year-over-year increase in Q1 EPS results on Wednesday..
Aprea Therapeutics shares are trading higher on continued strength after the co...
05-15 20:53
Aprea Therapeutics Reports Promising Q1 2025 Results
Aprea Therapeutics ( ($APRE) ) has issued an update. On May 14, 2025, Aprea The...
05-14 20:26
Aprea Therapeutics GAAP EPS of -$0.66
Aprea Therapeutics press release (NASDAQ:APRE): Q1 GAAP EPS of -$0.66. $19.3 million in cash and cash equivalents as of March 31, 2025, providing runway into early Q2 2026. More on Aprea Therapeutics ...
05-14 20:19
